

## Decree

### No .../2026 (of date) of the Minister for the Interior

#### amending Decree No 78/2022 of 28 December of the Ministry of the Interior on controlled substances

[1] A key objective is to take effective action against the spread of designer drugs and to minimise the health and social problems resulting from their consumption.

[2] By adding the new substances to the list, they are subject to the same legal assessment as narcotic drugs: their production, distribution, possession or consumption may have criminal consequences.

[3] Thanks to the measure and strict control, risks to public health, including the exposure of the target consumer group, can be reduced.

[4] Based on the authorisation granted under Section 32(5a) of Act XCV of 2005 on medicinal products for human use and on the amendment of other regulations related to medicinal products, and acting within my duties as defined in Section 66(1)(26) of Government Decree No 182/2022 of 24 May on the scope of duties and powers of members of the Government, I hereby order the following:

#### Section 1

(1) In Decree No 78/2022 of 28 December of the Ministry of the Interior on controlled substances (hereinafter: 'the Decree'), Annex 2 is amended in accordance with Annex 1 hereto.

(2) Annex 3 to the Decree is amended in accordance with Annex 2 hereto.

#### Section 2

In the Decree,

- a) in field A:38 of the table in Annex 1, section 1, subsection 1.1, the words 'Cyclopropylfentanyl' are replaced by 'Cyclopropylfentanyl',
- b) in fields C:6, C:7, C:8 and C:115 of the table in Annex 2, section 1, subsection 1.1, the words 'EU2' are replaced by the words 'EU',
- c) in fields A:38 and C:38 of the table in Annex 2, section 1, subsection 1.1, the words 'EU3' are replaced by the words 'EU',
- d) in field A:51 of the table in Annex 2, section 1, subsection 1.1, the words '(1,3-DMAA)' are replaced by '(1,3-DMAA)\*\*\*',
- e) in field C:104 of the table in Annex 2, section 1, subsection 1.1, the words 'EU1' are replaced by 'EU',
- f) in field A:116 of the table in Annex 2, section 1, subsection 1.1, the words '3-MMC' are replaced by '3-MMC<sup>EU</sup>',
- g) in field A:117 of the table in Annex 2, section 1, subsection 1.1, the words '3-CMC' are replaced by the words '3-CMC<sup>EU</sup>'

#### Section 3

Rows 177 and 183 of the table in section 6, subsection 6.1 of Annex 3 of the Decree are removed.

#### **Section 4**

This Decree shall enter into force on the tenth day following its publication.

#### **Section 5**

The requirement for the prior notification of this draft decree, as stipulated in Articles 5 to 7 of Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services, has been met.

1. Field C:116 of the table in section 1, subsection 1.1 of Annex 2 of the Decree is replaced by the following field:

	[ C ]
	[Chemical name / Description]
“	
[116]	2-(methylamino)-1-(3- methylphenyl)propan-1- one <sup>EU</sup>

”

2. Field C:117 of the table in section 1, subsection 1.1 of Annex 2 of the Decree is replaced by the following field:

	[ C ]
	[ Chemical name / Description ]
“	
[117]	1-(3-chlorophenyl)-2- (methylamino)propan-1- one <sup>EU</sup>

”

3. The following rows 50 and 51 are added to the table in section 2, subsection 2.1 of Annex 2 of the Decree:

	<i>A</i>	<i>B</i>	<i>C</i>	<i>D</i>	<i>E</i>
1	<i>Official name (Hungarian name)</i>	<i>Other name or abbreviation, spelling commonly used abroad</i>	<i>Chemical name / Description</i>	<i>Molecular formula</i>	<i>InChIKey chemical identifier]</i>

“

50	Modafinil sulphone***		2-[(diphenylmethyl)sulfonyl]acetamide	C <sub>15</sub> H <sub>15</sub> NO <sub>3</sub> S	ZESNOWZYHYRSRY- UHFFFAOYSA-N
51	Modafinil***		2-[(diphenylmethyl)sulfinyl]acetamide	C <sub>15</sub> H <sub>15</sub> NO <sub>2</sub> S	YFGHCGITMMYXAQ- UHFFFAOYSA-N

”

The following rows 388–394 are added to the table in section 6, subsection 6.1 of Annex 3 of the Decree:

	<i>A</i>	<i>B</i>	<i>C</i>	<i>D</i>
1	<i>Official name (or other name or abbreviation, or another type of spelling commonly used abroad)</i>	<i>Chemical name</i>	<i>Molecular formula</i>	<i>InChIKey chemical identifier]</i>

“

388	HHC-C8	3-octyl-6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol	C <sub>24</sub> H <sub>38</sub> O <sub>2</sub>	JOHVFVHLPAPLSA-UHFFFAOYSA-N
389	2-Br-HHC-O-acetate	2-bromo-6,6,9-trimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-yl acetate	C <sub>23</sub> H <sub>33</sub> BrO <sub>3</sub>	CISPFEQXHGXYRW-UHFFFAOYSA-N
390	mephenaqualone	8-methoxy-3-(2-methylphenyl)-2-phenylquinazolin-4(3H)-one	C <sub>22</sub> H <sub>18</sub> N <sub>2</sub> O <sub>2</sub>	BWXQPJORBOGKST-UHFFFAOYSA-N
391	ethylbromazolam	8-bromo-1-ethyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine	C <sub>18</sub> H <sub>15</sub> BrN <sub>4</sub>	DKTGBMWVWLATMHK-UHFFFAOYSA-N
392	CL-218,872	3-methyl-6-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[4,3-b]pyridazine	C <sub>13</sub> H <sub>9</sub> F <sub>3</sub> N <sub>4</sub>	GUOQUXNJZHGPQF-UHFFFAOYSA-N
393	N-pyrrolidino ethylene isotonitazene	5-nitro-2-(2-{4-[(propan-2-yl)oxy]phenyl}ethyl)-1-[2-(pyrrolidin-1-yl)ethyl]-1H-1,3-benzimidazole	C <sub>24</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub>	BCRJRRWYLQWRPJ-UHFFFAOYSA-N
394	clonazafone	2-amino-N-{2-[2-(2-chlorobenzoyl)-4-nitroanilino]-2-oxoethyl}acetamide	C <sub>17</sub> H <sub>15</sub> ClN <sub>4</sub> O <sub>5</sub>	CDNZKQZDZGOQET-UHFFFAOYSA-N

”

